Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clebopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.91 |
| ▸ | HTR4 known ✓ | Q13639 | 6/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | DRD4 | P21917 | 8/20 | 0.91 |
| ▸ | DRD3 | P35462 | 6/20 | 0.91 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.91 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.91 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.91 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.91 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.91 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.91 |
| ▸ | ACHE | P22303 | 1/20 | 0.91 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.91 |
| ▸ | HTR2A | P28223 | 1/20 | 0.91 |
| ▸ | HTR2C | P28335 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.91 |
| ▸ | HTR2B | P41595 | 1/20 | 0.91 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.91 |
| ▸ | HTR3A | P46098 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clebopride SCHEMBL2323725 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD4DRD2DRD3CYP1A2 | |
| Clebopride SCHEMBL4537448 | 1.00 | CYP3A4 (1.00) | CYP3A4DRD4DRD2DRD3CYP1A2 | |
| Clebopride SCHEMBL25259199 | 0.95 | DRD4 (1.00) | CYP3A4DRD4DRD2DRD3CYP1A2 | |
| Clebopride SCHEMBL25710 | 0.95 | DRD4 (1.00) | CYP3A4DRD4DRD2DRD3CYP1A2 | |
| Clebopride SCHEMBL9867307 | 0.94 | DRD4 (0.98) | CYP3A4DRD4DRD2DRD3CYP1A2 | |
| SCHEMBL11533888 | 0.92 | DRD4 (0.92) | CYP3A4DRD4DRD2DRD3CYP1A2 | |
| SCHEMBL11472928 | 0.90 | DRD4 (1.00) | CYP3A4DRD4DRD2DRD3CYP1A2 | |
| Fumaric Acid SCHEMBL11454163 | 0.88 | DRD4 (0.79) | CYP3A4DRD4DRD2DRD3CYP1A2 | |
| Clebopride SCHEMBL3701285 | 0.87 | DRD4 (0.83) | CYP3A4DRD4DRD2DRD3CYP1A2 | |
| SCHEMBL14454215 | 0.85 | DRD4 (0.80) | CYP3A4DRD4DRD2DRD3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20110217371-A1 | CONTROLLED-RELEASE MICROPARTICLES AND METHOD OF PREPARING SAME | AMOREPACIFIC CORPORATION (KR) | 2011-09-08 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-2958891-B1 | RED FLUORESCENT ALDEHYDE DEHYDROGENASE (ALDH) SUBSTRATE | UNIV JOHNS HOPKINS (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10156521-B2 | Red fluorescent aldehyde dehydrogenase (ALDH) substrate | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-12-18 | — | — | US | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170165230-A1 | USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY | RUDD CHRISTOPHER (CA) | 2017-06-15 | — | — | US | disclosed |
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | disclosed |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-07-16 | — | — | US | disclosed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | DRD2 240/4885HTR4 59/4885CYP3A4 4502/4885 |
| US-10156521-B2 | Red fluorescent aldehyde dehydrogenase (ALDH) substrate | ALDH3A1, ALDH2, ALDH1A2 | DRD2 1980/4885HTR4 3945/4885CYP3A4 1149/4885 |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | SIGMAR1, GPR119, TMEM97 | DRD2 265/4885HTR4 29/4885CYP3A4 425/4885 |
| US-10004701-B2 | Methods and compositions for treating infection | MMP8, IFNG, MPO | DRD2 4694/4885HTR4 4626/4885CYP3A4 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.